WallStSmart

Merck & Company Inc (MRK)vsRevvity Inc. (RVTY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2166% more annual revenue ($65.77B vs $2.90B). MRK leads profitability with a 13.6% profit margin vs 8.3%. RVTY appears more attractively valued with a PEG of 0.64. RVTY earns a higher WallStSmart Score of 54/100 (C-).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

RVTY

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 5.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: 2.00
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-42.4%)

Margin of Safety

-42.4%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for RVTY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

RVTY2 strengths · Avg: 8.0/10
PEG RatioValuation
0.648/10

Growing faster than its price suggests

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVTY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
3.5%4/10

3.5% earnings growth

Return on EquityProfitability
3.4%3/10

ROE of 3.4% — below average capital efficiency

P/E RatioValuation
50.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : RVTY

The strongest argument for RVTY centers on PEG Ratio, Price/Book. PEG of 0.64 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : RVTY

The primary concerns for RVTY are EPS Growth, Return on Equity, P/E Ratio. A P/E of 50.1x leaves little room for execution misses.

Key Dynamics to Monitor

RVTY carries more volatility with a beta of 1.11 — expect wider price swings.

RVTY is growing revenue faster at 7.0% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVTY scores higher overall (54/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Revvity Inc.

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.

Want to dig deeper into these stocks?